CBD製品は痛みを和らげず、潜在的に有害であることが新たな研究で判明(CBD products don’t ease pain and are potentially harmful – new study finds)

ad

2024-03-25 バース大学

バース大学の新しい研究によれば、CBD製品が慢性疼痛を軽減するという証拠はなく、それらを摂取することは金の無駄であり、健康にも潜在的に害を及ぼす可能性がある。CBDは大麻植物に自然に含まれる化合物の1つであり、痛みの代替治療法として人気があるが、今回の研究によれば、これらの製品は避けるべきだとされている。CBD製品は消費者に様々な量のCBDを提供しており、時には広告されている量以上のものも含まれている。また、非医療用のCBD製品は、内容物や品質が一貫していないため、消費者保護の観点から注意が必要である。

<関連情報>

痛みのためのカンナビジオール(CBD)製品:効果がなく、高価で、潜在的な害がある Cannabidiol (CBD) Products for Pain: Ineffective, Expensive, and With Potential Harms

Andrew Moore,Sebastian Straube,Emma Fisher,Christopher Eccleston
The Journal of Pain  Published:October 18, 2023
DOI:https://doi.org/10.1016/j.jpain.2023.10.009

CBD製品は痛みを和らげず、潜在的に有害であることが新たな研究で判明(CBD products don’t ease pain and are potentially harmful – new study finds)

Highlights

•Cannabidiol (CBD) products have varying amounts of CBD, from none to much more than advertised.

•CBD products may contain other chemicals than CBD, some of which may be harmful.

•Sixteen RCTs for pain used pharmaceutical CBD in oral, buccal/sublingual, and topical forms.

•Fifteen of the 16 RCTs were negative: no greater pain-relieving effect for CBD than for placebo.

•Meta-analyses link CBD to increased rates of serious adverse events and hepatotoxicity.

Abstract

Cannabidiol (CBD) attracts considerable attention for promoting good health and treating various conditions, predominantly pain, often in breach of advertising rules. Examination of available CBD products in North America and Europe demonstrates that CBD content can vary from none to much more than advertised and that potentially harmful other chemicals are often included. Serious harm is associated with chemicals found in CBD products and reported in children, adults, and the elderly. A 2021 International Association for the Study of Pain task force examined the evidence for cannabinoids and pain but found no trials of CBD. Sixteen CBD randomized trials using pharmaceutical-supplied CBD or making preparations from such a source and with pain as an outcome have been published subsequently. The trials were conducted in 12 different pain states, using 3 oral, topical, and buccal/sublingual administration, with CBD doses between 6 and 1,600 mg, and durations of treatment between a single dose and 12 weeks. Fifteen of the 16 showed no benefit of CBD over placebo. Small clinical trials using verified CBD suggest the drug to be largely benign; while large-scale evidence of safety is lacking, there is growing evidence linking CBD to increased rates of serious adverse events and hepatotoxicity. In January 2023, the Food and Drug Administration (FDA) announced that a new regulatory pathway for CBD was needed. Consumers and health care providers should rely on evidence-based sources of information on CBD, not just advertisements. Current evidence is that CBD for pain is expensive, ineffective, and possibly harmful.

Perspective
There is no good reason for thinking that CBD relieves pain, but there are good reasons for doubting the contents of CBD products in terms of CBD content and purity.

有機化学・薬学
ad
ad
Follow
ad
タイトルとURLをコピーしました